Single Follicular Dexarelix for LH Suppression During Ovarian Stimulation in Oocyte Donors.

Assisting Nature

Status

Unknown

Conditions

Infertility

Premature Ovarian Failure

Treatments

Diagnostic Test: live birth rate

Study type

Observational

Funder types

Other

Identifiers

NCT03861715

Single-VS-multiple dose- AN007

Details and patient eligibility

About

A randomized prospective study in the evaluation of the long acting GnRH antagonist Degarelix against the classical multidose regime with Ganirelix for LH suppression during the follicular phase of an ovarian stimulation cycle in oocyte donors.

Full description

A randomized prospective study of the use of single dose of the long acting GnRH antagonist Degarelix for ovarian stimulation cycle in oocyte donors: Ovarian stimulation started on cycle Day2 with gonadotropins 175-300 IU and either GnRH antagonist single dose Degarelix or multidose GnRH antagonist Ganirelix initiated on Day6 of the stimulation cycle. Agonist triggering was used in both groups for oocyte maturation. Blastocyst formation rate and Live Birth Rates were estimated for both groups.

Enrollment

180 estimated patients

Sex

Female

Ages

20 to 34 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

age 20-34 years;
body mass index (BMI) 18-29kg/m2;
regular menstrual cycle of 26-35 days,
AMH levels age appropriate (≥2.3 ng/ml)
early follicular- phase serum concentration of FSH within normal limits (1-12 IU/l).

Exclusion criteria

women with diabetes and other metabolic disease
women with hereditary genetic diseases;
women with heart disease, QT prolongation,heart failure
elevated liver enzymes, liver failure, hepatitis
women with inflammatory or autoimmune disease
abnormal karyotype;
endometriosis stage III/IV;
history of recurrent miscarriage;
severe OHSS in a previous stimulation cycle or any contraindication for the use of gonadotrophins.